对输卵管原发性癌患者进行CA 125的系列测定。
Serial measurement of CA 125 in patients with primary carcinoma of the fallopian tube.
作者信息
Tokunaga T, Miyazaki K, Matsuyama S, Okamura H
机构信息
Department of Obstetrics and Gynecology, Kumamoto National Hospital, Japan.
出版信息
Gynecol Oncol. 1990 Mar;36(3):335-7. doi: 10.1016/0090-8258(90)90137-a.
Serial assay of serum CA 125 was carried out in five patients with advanced primary carcinoma of the fallopian tube. Pretreatmental levels of these patients were elevated, ranging from 145 to 535 U/ml (305 +/- 140.1, mean +/- SD). All patients showed rapid decreases in response to treatment; however, reelevations were noted in two patients concomitant with recurrence. In the remaining three patients, who are alive with no evidence of recurrence at 52, 29, and 21 months, serum CA 125 levels remained below 5 U/ml after remission. These results suggest that CA 125 is useful in monitoring patients with primary carcinoma of the fallopian tube.
对5例晚期原发性输卵管癌患者进行了血清CA 125的系列检测。这些患者治疗前的水平升高，范围为145至535 U/ml（均值±标准差为305±140.1）。所有患者对治疗均表现出快速下降；然而，有2例患者在复发时CA 125水平再次升高。其余3例患者分别在52、29和21个月时存活且无复发迹象，缓解后血清CA 125水平仍低于5 U/ml。这些结果表明，CA 125在监测原发性输卵管癌患者方面是有用的。
Zotero 插件